infection

Trial

Entasis Therapeutics Announces Positive Topline Results for Sulbactam-durlobactam (SUL-DUR) From Phase 3 ATTACK Trial

Entasis Therapeutics Holdings Inc. (Nasdaq:ETTX), a clinical-stage biopharmaceutical company focused on the discovery and development of novel antibacterial products, today announced topline results from its ATTACK trial―a global Phase 3 registrational trial evaluating the safety and efficacy of SUL-DUR versus colistin in patients with infections caused by Acinetobacter baumannii.
1 2 3 4 5 6
Real Time Analytics